Cogent Hits Mark In Phase III GIST Trial Of Bezuclastinib

 
• By Alaric DeArment
  
Cancer cells on scientific background.3d illustration
Cogent reported positive results from its Phase III PEAK study of bezuclastinib in GIST. • Source: Shutterstock

More from Clinical Trials

More from R&D